Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults exhibited that it generated virus-neutralizing antibodies at levels similar to those observed in younger adults, with side effects roughly on par with high-dose flu shots, researchers said on Tuesday.The study, published in the New England Journal of Medicine, provides a more wholesome idea of the vaccine’s safety in older adults, a group at an amplified risk of severe complications from COVID-19.The findings are reassuring as immunity leans towards a weaker side with age, Dr.
Evan Anderson, one of the study’s lead researchers from Emory University in Atlanta, explained in a phonetic interview.The study acted as an extension of Moderna’s Phase.
Read more on toopanda.com